A practical reference on alpha-MSH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Like other bacteriocins, the halocins are under investigation as antimicrobials for use in controlling spoilage during industrial processes; in this case, leather production. Because the literature about halocins is relatively circumscribed, it can be exhaustively cited. Several times they have been addressed in book chapters. BACTIBASE database is an open-access database for bacteriocins including halocins (view complete list).
== Fatty acids and insulin == Fatty acids may act directly upon the pancreatic β-cell to regulate glucose-stimulated insulin secretion. This effect is biphasic. Initially fatty acids potentiate the effects of glucose. After prolonged exposure to high fatty acid concentrations this changes to an inhibition. Randle suggested that the term fatty acid syndrome would be appropriate to apply to the biochemical syndrome resulting from the high concentration of fatty acids and the relationship to abnormalities of carbohydrate metabolism, including starvation, diabetes and Cushing’s syndrome.
=== Environmental triggers === Environmental factors, such as glandular viral infection, could prompt epithelial cells to activate the HLA-independent innate immune system through toll-like receptors. Although several infectious, exogenous agents have been implicated in the pathogenesis of Sjögren's disease, such as Epstein-Barr virus (EBV), human T-lymphotropic virus 1, and hepatitis C virus, their association with Sjögren's disease appears weak. While EBV is present in the salivary glands of normal individuals, a high incidence of EBV reactivation in Sjögren's patients has been reported with increased levels of EBV DNA. This indicates viral reactivation and the inability of lymphoid infiltrates to control EBV replication in Sjögren's disease, leading to the initiation or perpetuation of an immune response in target organs. Nonetheless, exactly how EBV reactivation is induced in lesions of patients with Sjögren's disease, and which specific molecular mechanisms are involved in the process of viral reactivation, remain to be clarified.
=== Attribution === Portions of the text of this article originate from NIH Publication No. 02-4806, a public domain resource. "What I need to know about Prostate Problems". National Institutes of Health. 2002-06-01. No. 02-4806. Archived from the original on 2002-06-01. Retrieved 2011-01-24.
Sources: en.wikipedia.org
The defense along the Vistula took place from August 1944 until the renewed Soviet offensive in January 1945. By January 1945, the 4th Panzer Army was holding static defensive positions on Hitler's direct orders and during the lull in the fighting it had created a defensive zone in southern Poland. On 1 January 1945, the 4th Panzer Army, then under Army Group A, had a total strength of 133,474 men spread across seven infantry divisions (68th, 72nd, 88th, 168th, 291st, 304th, 342nd), two Panzergrenadier divisions (10th, 20th), two panzer divisions (16th, 17th), two autonomous brigades, an autonomous regiment and several autonomous artillery detachments. With its manpower, it was the largest single contributor to Army Group A's overall manpower of 400,556. Unknown to the Wehrmacht, the Soviet command planned to saturate the entire defensive zone with artillery bombardment. The Red Army began their Vistula–Oder Offensive on January 17, quickly encircling the LVI Panzer Corps and destroying half of all armoured forces concentrated with the 4th Panzer Army. The commander of the LVI Corps, General Johannes Block, was killed in action on 26 January. The remnants of the army retreated along the entire front before re-grouping on the western bank of the Oder River in February 1945. The Red Army halted its offensive in February 1945. The 3rd Panzer Army was tasked to halt the Soviets in the north, while the 9th Army was guarding against the Soviets in the centre.
== Physiological potential == In a pre-clinical meta-analysis of gingerol compounds anticancer, anti-inflammatory, anti-fungal, antioxidant, neuroprotective and gastroprotective properties were reported, which include studies in-vitro and in-vivo. A few in-vivo studies have proposed that gingerols facilitate healthy glucose regulation for diabetics. Many studies have been around the effects of gingerols on a wide range of cancers including leukemia, prostate, breast, skin, ovarian, lung, pancreatic and colorectal. There has not been much clinical testing to observe gingerols physiological impacts in humans. While many of the chemical mechanisms associated with the effects of gingerols on cells have been thoroughly studied, few have been in a clinical setting. This is due to the high variability in natural phytochemicals and the lack of efficacy in research. Most herbal medicine, which include gingerols, are under the restrictions of the Food and Drug Administration in the United States and experimental methods have not held up to scrutiny which has decreased the value in phytochemical research. Herbal medicine is untested for quality assurance, potency and effectiveness in clinical settings due to a lack of funding in eastern medical research. Most research on [6]-Gingerol has been on either mouse subjects (in-vivo) or on cultured human tissue (in-vitro) and may be used in the future to discuss possible applications for multi-target disease control.
=== Small RNA molecules regulate gene expression by post-transcriptional gene silencing === Another previously unknown mechanism by which RNA molecules are involved in genetic regulation was discovered in the 1990s. Small RNA molecules termed microRNA (miRNA) and small interfering RNA (siRNA) are abundant in eukaryotic cells and exert post-transcriptional control over mRNA expression. They function by binding to specific sites within the mRNA and inducing cleavage of the mRNA via a specific silencing-associated RNA degradation pathway.
The Appalachian Mountains contain major deposits of anthracite coal as well as bituminous coal. In the folded mountains the coal is in metamorphosed form as anthracite, represented by the Coal Region of northeastern Pennsylvania. The bituminous coal fields of western Pennsylvania, western Maryland, southeastern Ohio, eastern Kentucky, southwestern Virginia, and West Virginia contain the sedimentary form of coal. The mountain top removal method of coal mining, in which entire mountain tops are removed, is currently threatening vast areas and ecosystems of the Appalachian Mountain region. The surface coal mining that started in the 1940s has significantly impacted the central Appalachian Mountains in Kentucky, Tennessee, Virginia and West Virginia. Early mining methods were unregulated and mined land reclamation research, including acid base accounting, was led by the West Virginia University in the 1960s and 1970s. West Virginia developed rigorous mine reclamation standards for state coal mines in the late 1960s. Regulations were introduced by most states to protect the Appalachian Mountains by the late 1960s. Social and political activism brought about the Surface Mining Control and Reclamation Act of 1977. The 1859 discovery of commercial quantities of petroleum in the Appalachian Mountains of western Pennsylvania started the modern United States petroleum industry. Recent discoveries of commercial natural gas deposits in the Marcellus Shale formation and Utica Shale formations have once again focused oil industry attention on the Appalachian Basin.
==== Removing excess coolant ==== After the area to be branded is cleaned and soaked with alcohol, the brand is removed from its coolant. It is very important to shake the brand vigorously to remove as much coolant as possible from its working surface. This is necessary because drips of coolant are capable of freezing an animal's skin on their own as they roll down its body, producing a permanent drip mark down the hide of the animal. It is also necessary because the dynamic viscosity of ethanol greatly increases at cryogenic temperatures, rising more than eight-fold from room temperatures. The thicker alcohol necessitates a more thorough shaking than one would give the same brand covered in water.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.